Skip to search formSkip to main contentSkip to account menu

MS 209

Known as: MS-209, MS209 
National Institutes of Health

Related topics

Related topics

2 relations
Dofequidar Fumarate

Broader (1)

dofequidar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
99mTc‐MIBI imaging for prediction of therapeutic effects of second‐generation MDR1 inhibitors in malignant brain tumors
The aim of this study was to explore whether 99mTc‐methoxyisobutylisonitrile (99mTc‐MIBI) is suitable to elucidate multidrug… 
Review
2004
Review
2004
MS-209 Schering.
MS-209, a quinolone-derived sphingomyelin synthase inhibitor that blocks P-glycoprotein and multidrug resistance-associated… 
Review
2001
Review
2001
All-trans Retinoic Acid (ATRA) Differentiates Acute Promyelocytic Leukemia Cells Independently of P-Glycoprotein (P-gp) Related Multidrug Resistance
Here the relationship between all-trans retinoic acid (ATRA)-resistance and P-glycoprotein (P-gp)-associated multidrug resistance… 
2001
2001
A New Quinoline Derivative MS‐209 Reverses Multidrug Resistance and Inhibits Multiorgan Metastases by P‐glycoprotein‐expressing Human Small Cell Lung Cancer Cells
Development of distant metastases and acquired multidrug resistance (MDR) are major problems in therapy for human small cell lung… 
Review
2000
Review
2000
Multidrug resistance of acute leukemia and a strategy to overcome it.
A representative cause of multidrug resistance (MDR) is expression of the MDR gene (mdr1) and its product P-glycoprotein (P-gp… 
Review
2000
Review
2000
[New combination therapies in hematological malignancies].
New combination therapies against hematological malignancies have recently been reported. Anti-CD20 chimeric antibody adds a… 
1998
1998
Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil
Purpose and methods: To develop a clinically useful approach to circumvent P-glycoprotein (P-gp)-mediated multidrug resistance… 
1998
1998
Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209.
P-glycoprotein (Pgp), a membrane drug efflux pump, is thought to be responsible for the observed drug resistance in osteosarcoma… 
1997
1997
Recovery of drug sensitivity by MS‐209, a new multidrug resistance‐reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line
Abstract: The efficacy of MS‐209, a quinoline derivative synthesized as a new multidrug resistance (MDR)‐reversing agent, was… 
Review
1997
Review
1997
[Mechanism of multidrug resistant tumors and chemotherapeutic approaches against the resistant tumors].
  • T. Tsuruo
  • Yakugaku zasshi : Journal of the Pharmaceutical…
  • 1997
  • Corpus ID: 23856860
Research on multidrug resistance (MDR) has spread widely, with the emphasis on the development of therapeutic approaches. This… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)